Company Filing History:
Years Active: 2022
Title: Felix Herth: Innovator in Cancer Treatment Identification
Introduction
Felix Herth, based in Heidelberg, Germany, is a notable inventor recognized for his contributions to the field of cancer diagnostics. With one patent to his name, he has made significant strides in identifying individuals who may benefit from chemotherapy treatment.
Latest Patents
His patent, titled "Methods of identifying an individual to be treated by chemotherapy based on cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) marker molecules and related uses," provides a groundbreaking approach in the identification of patients with non-small cell lung carcinoma. The method utilizes specific marker molecules, namely cytokeratin-19 fragments and carcinoembryonic antigen, to ascertain the necessity of chemotherapy for affected individuals.
Career Highlights
Felix Herth is associated with Roche Diagnostics Operations, Inc., where his work focuses on innovative solutions in medical diagnostics. His expertise has contributed to the advancement of methodologies that enhance patient care and treatment precision.
Collaborations
Throughout his career, Felix has collaborated with significant figures in the industry, such as Friedemann Krause and Vinzent Rolny. These partnerships have fostered an environment of innovation and have enhanced the scope of research and development in cancer diagnostics.
Conclusion
Felix Herth's work represents a crucial advancement in oncology, exemplifying how innovative patents can impact patient diagnosis and treatment. His dedication to research and collaboration underscores the importance of teamwork in the pursuit of medical breakthroughs.